• Cover / Corporate Communications Tools / Contents [PDF:262KB]
• Value Creation Story [PDF:1,211KB]
• Mitsubishi Tanabe Pharma's Value Creation Model [PDF:76KB]
• Strengths [PDF:469KB]
• Materiality [PDF:69KB]
• Business / Strategy [PDF:31KB]
• Approach to Value Creation [PDF:37KB]
• Providing Value to Society [PDF:625KB]
• Financial and Non-Financial Highlights [PDF:39KB]

• Business and Financial Strategy [PDF:2,351KB]
• Message from the President [PDF:788KB]
• Message from the Financial and Accounting Officer [PDF:134KB]
• U.S. Business [PDF:573KB]
• Business Strategies by Process [PDF:921KB]
  • Drug Discovery [PDF:469KB]
  • Pipeline [PDF:32KB]
  • Drug Fostering and Evolution [PDF:101KB]
  • Supply Chain [PDF:214KB]
  • Marketing [PDF:190KB]

Non-Financial Information [PDF:759KB]

• Corporate Governance [PDF:45KB]
• Risk Management [PDF:51KB]
• A Message from an Outside Director [PDF:125KB]
• Member of the Board and Corporate Auditors [PDF:247KB]
• Reliable Products and Sustainable Supply [PDF:170KB]
• Appropriate Use of Products [PDF:35KB]
• Ethics, Fairness and Sincerity in Business Practices [PDF:35KB]
• Stakeholder Engagement [PDF:41KB]
• Employee Health, Diversity and Inclusion [PDF:63KB]
• Social Contribution Activities for Health [PDF:58KB]
• Environmental Initiatives [PDF:101KB]

Operating Results and Data [PDF:687KB]

• 10-Year Financial Summary [PDF:30KB]
• Management's Discussion and Analysis [PDF:51KB]
• Operational Risks [PDF:31KB]
• Overview and Sales Trends of Priority Products [PDF:585KB]
• Consolidated Statement of Income [PDF:24KB]
• Consolidated Statement of Comprehensive Income [PDF:25KB]
• Consolidated Statement of Financial Position [PDF:27KB]
• Consolidated Statement of Changes in Equity [PDF:31KB]
• Consolidated Statement of Cash Flows [PDF:26KB]
• Explanation of Terms [PDF:25KB]
• History [PDF:32KB]
• Corporate Data / Investor Information [PDF:35KB]

• CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITOR’S REPORT [PDF:1,064KB]